Metra Biosystems

Metra Biosystems was a specialized biotechnology company focused on the development and commercialization of diagnostic products for the assessment of bone and cartilage metabolism. The company's primary focus was on managing metabolic bone diseases, such as osteoporosis, and joint diseases like arthritis. Their product line included proprietary immunoassays that measured specific biochemical markers in urine and blood to monitor bone resorption and formation. Metra's technology provided clinicians with tools to evaluate the effectiveness of therapies and assess the risk of bone loss. The company was acquired by Quidel Corporation in 1999 to strengthen Quidel's position in the point-of-care and specialty diagnostics markets.